Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Notification Calls for Cooperation to Prevent Local Shortages of Rubella Vaccine
July 5, 2013
- Health Ministry to Give Guidance to Parties Suspected of Data Manipulation in Anti-Obesity Drug Clinical Study
July 4, 2013
- Expiration Date for Tamiflu Capsules Extended from 7 to 10 Years
July 3, 2013
- Notification Calls for Simultaneous Filing of Applications for Companion Diagnostics and Drugs
July 3, 2013
- Deputy Mayor of Ikoma Proposes Reduction of Dispensing Fees for Pharmacies With Low Generic Dispensing Rates
July 2, 2013
- MHLW Project Stops Short of Setting Generic Evaluation Criteria
July 1, 2013
- Price Settlement Rate for Chain Pharmacies Fell Below 50% in FY2012: Survey
July 1, 2013
- MHLW Aims for Passage of Bill to Amend PAL during Extraordinary Diet Session This Autumn
July 1, 2013
- Study Group Approves Guidelines for Use of Medical Information Database During Trial Period
June 28, 2013
- Cost-Effective Assessment for Medical Devices Presented at CSIMC Subcommittee; Reps Say They Want Examples for Pharmaceuticals Too
June 27, 2013
- MHLW Maps Out New Vision for Pharma Industry; Research-Based Makers Will See “Survival of the Fittest,” It Says
June 27, 2013
- HSC’s Vaccination Policy Committee Approves Switch to 13-Valent Pediatric Pneumococcal Vaccine
June 26, 2013
- Patients Would Like to See Their Drug Costs Reduced by Half; Further Reductions in Generic Drug Prices to Become a Topic: Pharmaceutical Management Director Chikazawa
June 25, 2013
- LDP Election Platform Targets 16 Trillion Yen Healthcare Market in 2020
June 24, 2013
- 47 Products Including an AG of Allegra, but not That of Livalo, Added to NHI Price List in Latest Generic Listing
June 24, 2013
- First Generics for 5 Products Including Prograf, TS-1 Added to NHI Drug Price List
June 24, 2013
- FPMAJ May Find it Difficult to Compile Unified Statement of Views on TPP Talks Due to Disagreement among Original and Generic Drug Makers
June 24, 2013
- MHLW to Resume Inviting Requests for Development of Unapproved Drugs, Indications; No Deadline Set This Time
June 20, 2013
- MHLW to Quickly Compile Studies on Reported HPV Vaccine Adverse Events, Give Clear Explanation to Public: Minister Tamura
June 20, 2013
- Top Priorities for Next Midterm Plan to Include Greater Sophistication in Review and Consultation: PMDA
June 20, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…